Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SA1 siRNA
- Development stage
- Unknown
- Modality
- Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
**SA1 siRNA** is a small interfering RNA molecule designed to silence specific gene expression via RNA interference (RNAi). siRNA drugs act by targeting messenger RNA (mRNA) with high sequence specificity, leading to mRNA cleavage and subsequent gene silencing at the post-transcriptional level. Upon cellular entry, double-stranded SA1 siRNA is incorporated into the RNA-induced silencing complex (RISC), where it is unwound and the antisense strand guides RISC to the complementary mRNA. The Argonaute-2 (Ago-2) protein within RISC then cleaves the targeted mRNA, preventing translation of the encoded protein[1][3][5][7]. This mechanism is highly specific, transient, and reversible, minimizing permanent genomic changes[3]. No information from provided sources identifies the developer, manufacturer, or specific target gene of the "SA1 siRNA" molecule, nor clinical trial information.
- Brand names
- SA1 siRNASA-1 siRNASA 1 siRNA
- Other names
- SA1 siRNASA-1 siRNASA 1 siRNA
02
Targets
PMEPA1 (Prostate transmembrane protein, androgen induced 1)
Beyond the preview
Go deeper on SA1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SA1 siRNA.